Related Experiment Videos
[Relationships between mental and cardiac diseases].
A Birkhofer1, G Schmidt, H Förstl
1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar Technische Universität München Ismaninger Str. 22, D-81675 München. andreas.birkhofer@lrz.tu-muenchen.de
MMW Fortschritte Der Medizin
|November 12, 2005
Summary
Patients with cardiac disease and depression benefit from selective serotonin reuptake inhibitors due to low interaction potential. Careful ECG monitoring is crucial for psychiatric medications to prevent cardiac arrhythmias.
Area of Science:
- Psychiatry
- Cardiology
- Pharmacology
Background:
- Mental illnesses like schizophrenia and affective disorders increase cardiovascular mortality risk.
- Patients with cardiac conditions experiencing depression require specific pharmacological considerations.
Purpose of the Study:
- To review the cardiovascular risks associated with psychotropic medications.
- To guide the selection of antidepressants and antipsychotics in cardiac patients.
- To emphasize the importance of electrocardiogram (ECG) monitoring.
Main Methods:
- Literature review of studies on psychotropic drugs and cardiovascular events.
- Analysis of drug interaction profiles, particularly QTc interval prolongation.
- Evaluation of ECG monitoring recommendations for psychiatric treatment.
Main Results:
- Selective serotonin reuptake inhibitors (SSRIs) like sertraline and citalopram have low interaction potential.
- Thioridazine, pimozide, and ziprasidone are associated with QTc prolongation; ziprasidone shows no link to sudden cardiac death.
- Baseline and follow-up ECGs are essential, especially with low-potency antipsychotics.
Conclusions:
- SSRIs are a safer choice for depressed cardiac patients.
- Ziprasidone may be preferred over thioridazine and pimozide due to cardiac safety profile.
- Proactive ECG monitoring and awareness of drug interactions are vital for managing psychiatric patients with heart disease.